Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of gD2-AS04 in Adolescent Females
NCT00224484Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2004
- Primary completion
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of Herpevac in herpes simplex (HSV) (3 arms), sponsored by GSK. Primary endpoint: Number of Subjects With Serious Adverse Events. Started Apr 2004; status: completed.
02
Drugs
Herpevac
03
Conditions
herpes simplex (HSV)
Beyond the preview
Go deeper on NCT00224484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00224484.